drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Donor T cells are engineered to express a CAR that binds CD19 on B cells; CAR signaling (CD3ΞΆ with co-stimulatory domains) activates T-cell cytotoxicity and cytokine release to eliminate malignant CD19+ B cells.
nci_thesaurus_concept_id
C199286
nci_thesaurus_definition
A preparation of allogeneic engineered T-lymphocytes expressing a lentiviral vector encoding chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and an anti-CD3 single chain antibody with the KDEL peptide fused to its C-terminus, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 CAR T-cells ThisCART19A specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. By eliminating TCR/CD3 expression, the potential induction of graft-versus-host disease (GvHD) by the donor T-cells is abrogated.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor T cells engineered with an anti-CD19 chimeric antigen receptor (CAR) engage CD19 on B cells. CAR signaling (CD3z plus co-stimulatory domains) activates T-cell cytotoxicity and cytokine release to lyse CD19+ malignant B cells; disruption of endogenous TCR/CD3 minimizes graft-versus-host disease risk.
drug_name
ThisCART19A
nct_id_drug_ref
NCT05776407